KYMR
KYMR
NASDAQ · Biotechnology

Kymera Therapeutics Inc

$86.08
+1.45 (+1.71%)
As of May 9, 1:15 AM ET ·
Financial Highlights (FY 2026)
Revenue
37.53M
Net Income
-298,013,223
Gross Margin
Profit Margin
-794.0%
Rev Growth
-5.8%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 63.8% 63.8%
Operating Margin -891.1% -802.0% 5.7% 5.2%
Profit Margin -794.0% -754.3% 4.3% 4.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 37.53M 39.82M 7.83B 9.20B
Gross Profit 5.00B 5.87B
Operating Income -334,442,478 -319,361,517 447.05M 479.50M
Net Income -298,013,223 -284,574,960 335.40M 415.81M
Gross Margin 63.8% 63.8%
Operating Margin -891.1% -802.0% 5.7% 5.2%
Profit Margin -794.0% -754.3% 4.3% 4.5%
Rev Growth -5.8% -5.8% +18.7% +14.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 7.29M 7.29M 1.80B 1.98B
Total Equity 3.47B 3.47B 3.36B 3.32B
D/E Ratio 0.00 0.00 0.53 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -326,480,158 -329,078,143 592.59M 664.46M
Free Cash Flow 369.62M 455.69M